|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In HCC, hexokinase II positivity was associated with large tumor size (>4 cm) (<i>p</i> = 0.046), CAIX positivity with vascular invasion (<i>p</i> = 0.005), and MCT4 positivity with extrathyroidal extension (<i>p</i> = 0.030).
|
28790533 |
2017 |
|
Adolescent idiopathic scoliosis
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
The coexistence of copy number variations (CNVs) and single nucleotide polymorphisms (SNPs) at a locus can result in distorted calculations of the significance in associating SNPs to disease.
|
30019117 |
2018 |
|
SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 3
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
The coexistence of copy number variations (CNVs) and single nucleotide polymorphisms (SNPs) at a locus can result in distorted calculations of the significance in associating SNPs to disease.
|
30019117 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Monocarboxylate transporter 4 (MCT-4) serves a key function in transporting lactate across the plasma membrane in various types of human cancer.
|
29113201 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, these findings illustrate the metabolic diversity of PDA described by MCT4, delineate pathways through which this lactate transporter supports cancer growth, and demonstrate that PDA can be rationally targeted based on metabolic addictions.
|
25497091 |
2014 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
High MCT4 levels in HNSCC have been associated with poor prognosis, but the role of MCT4 in the development and progression of this cancer is still poorly understood.
|
30211114 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of lactate/H⁺ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and The Cancer Genome Atlas data analyses.
|
25456395 |
2015 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The first IF method has been developed and optimised for detection of MCT 1 and MCT4 in cancer patient CTC.
|
25957999 |
2015 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we assessed the impact of the MCT1 inhibitor AZD3965 on cancer cell metabolism <i>in vitro</i> and <i>in vivo</i> Exposing human lymphoma and colon carcinoma cells to AZD3965 increased MCT4-dependent accumulation of intracellular lactate, inhibiting monocarboxylate influx and efflux.
|
28923861 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Monocarboxylate transporter-4 (MCT4), a monocarboxylic acid transporter, demonstrates significantly increased expression in the majority of malignancies.
|
30051648 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells.
|
30540938 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As such, the MCT4 gene provides a unique, potential therapeutic target for cancer.
|
26755530 |
2016 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This oncogene-induced transition to malignancy is "mirrored" by a loss of caveolin-1 (Cav-1) and an increase in MCT4 in adjacent stromal fibroblasts, functionally reflecting catabolic metabolism in the tumor microenvironment.
|
23860382 |
2013 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Given the relationships between MCT1 and MCT4 and cancer, they offer a unique opportunity for novel treatment strategies.
|
30416849 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The NP technology can modulate the glycolysis pathway by silencing MCT4 to induce tumor cell acidosis, and concurrently exacerbate oxidative stress in tumor cells via the Fenton-like reaction.
|
29276823 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Monocarboxylate transporters 1 and 4 (MCT1 and MCT4) are involved in tumour development and progression.
|
31827199 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This oncogene-induced transition to malignancy is "mirrored" by a loss of caveolin-1 (Cav-1) and an increase in MCT4 in adjacent stromal fibroblasts, functionally reflecting catabolic metabolism in the tumor microenvironment.
|
23860382 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Objective Many aggressive head and neck cancers contain 2 metabolically coupled tumor compartments: a glycolytic stromal compartment with low caveolin-1 (CAV1) and high monocarboxylate transporter 4 (MCT4) expression and a highly proliferative carcinoma cell compartment with high MCT1.
|
29232177 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In xenograft models, MCT4 had a significant impact on tumor metabolism and was required for rapid tumor growth.
|
25497091 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The monocarboxylate transporter 4 (MCT4) is a metabolic target in tumor biology because it mediates lactate transport across membranes resulting in antiapoptotic effects.
|
23881922 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This work reveals that different types of net acid extruding transporters, NHE1, NBCn1 and MCT4, are frequently expressed in patient mammary tumor tissue and demonstrates for the first time that they promote growth of TNBC human mammary tumors in vivo via distinct but overlapping mechanisms.
|
29363134 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results indicate the MCT4-inhibition-induced disruption of tumor intracellular pH holds promise as a therapy against not only HCC, but a broader spectrum of MCT4-overexpressing hyperglycolytic tumors.
|
31479685 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lactate and MCTs, especially MCT1 and MCT4, are important contributors to tumor aggressiveness.
|
31395464 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibition of MCT4 results in decreased tumor growth <i>in vitro</i> and <i>in vivo</i> Targeting lactate metabolism via MCT4 therefore provides a promising therapeutic approach for invasive urothelial carcinoma, especially in the basal subtype.
|
30262589 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Monocarboxylate transporters 1 and 4 (MCT1 and MCT4) are involved in tumor development and progression.
|
31017677 |
2019 |